---
input_text: CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts. Mucopolysaccharidosis
  type I (MPS I) is a lysosomal storage disorder (LSD). It is caused by mutations
  in the IDUA gene, which lead to the accumulation of the glycosaminoglycans dermatan
  and heparan sulfate. The CRISPR-Cas9 system is a new and powerful tool that allows
  gene editing at precise points of the genome, resulting in gene correction through
  the introduction and genomic integration of a wildtype sequence. In this study,
  we used the CRISPR-Cas9 genome editing technology to correct in vitro the most common
  mutation causing MPS I. Human fibroblasts homozygous for p.Trp402* (legacy name
  W402X) were transfected and analyzed for up to one month after treatment. IDUA activity
  was significantly increased, lysosomal mass was decreased, and next generation sequencing
  confirmed that a percentage of cells carried the wildtype sequence. As a proof of
  concept, this study demonstrates that CRISPR-Cas9 genome editing may be used to
  correct causative mutations in MPS I. LIST OF ABBREVIATIONS.
raw_completion_output: |-
  primary_disease: Mucopolysaccharidosis type I (MPS I)

  medical_actions: CRISPR-Cas9-mediated gene editing; gene correction; transfection; next generation sequencing

  symptoms: accumulation of glycosaminoglycans dermatan and heparan sulfate

  chemicals: 

  action_annotation_relationships: CRISPR-Cas9-mediated gene editing TREATS accumulation of glycosaminoglycans dermatan and heparan sulfate IN Mucopolysaccharidosis type I (MPS I); gene correction TREATS accumulation of glycosaminoglycans dermatan and heparan sulfate IN Mucopolysaccharidosis type I (MPS I)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  gene correction TREATS accumulation of glycosaminoglycans dermatan and heparan sulfate IN Mucopolysaccharidosis type I (MPS I)

  ===

extracted_object:
  primary_disease: MONDO:1012617
  medical_actions:
    - CRISPR-Cas9-mediated gene editing
    - gene correction
    - transfection
    - next generation sequencing
  symptoms:
    - accumulation of glycosaminoglycans dermatan and heparan sulfate
  action_annotation_relationships:
    - subject: CRISPR-Cas9-mediated gene editing
      predicate: TREATS
      object: accumulation of glycosaminoglycans dermatan and heparan sulfate
      qualifier: MONDO:1012617
      subject_extension: CRISPR-Cas9-mediated gene editing
    - subject: gene correction
      predicate: TREATS
      object: accumulation of glycosaminoglycans dermatan and heparan sulfate
      qualifier: MONDO:1012617
      subject_extension: gene correction
named_entities:
  - id: MONDO:0001586
    label: mucopolysaccharidosis type I
  - id: MONDO:1012617
    label: Mucopolysaccharidosis Type I (MPS I)
  - id: CHEBI:60285
    label: DOPE
  - id: MAXO:0001521
    label: nasal administration
  - id: MONDO:0011758
    label: Mucopolysaccharidosis type I Hurler (MPSIH)
  - id: MAXO:0000747
    label: hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0000487
    label: clinical assessment (growth measurement, kyphosis and genu velgum evaluation)
  - id: HP:0002808
    label: kyphosis
  - id: HP:0001376
    label: limited joint mobility
  - id: HP:0008807
    label: acetabular dysplasia
  - id: MAXO:0010034
    label: Corneal transplantation
  - id: HP:0007957
    label: Corneal clouding
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: HP:0000238
    label: Hydrocephalus
  - id: MAXO:0000068
    label: transplantation
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000526
    label: clinical examination
  - id: CHEBI:143889
    label: glycosaminoglycan (GAG)
  - id: HP:0004322
    label: short stature
  - id: HP:0005619
    label: thoracolumbar kyphosis
  - id: HP:0000943
    label: dysostosis multiplex
  - id: MONDO:0011759
    label: Hurler-Scheie syndrome
  - id: HP:0001387
    label: joint stiffness
  - id: HP:0000403
    label: recurrent otitis media
  - id: HP:0001999
    label: facial dysmorphism
  - id: HP:0002781
    label: Upper airway obstruction
  - id: HP:0001638
    label: Cardiomyopathy
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:58187
    label: Alginate
  - id: CHEBI:53412
    label: PLL (Poly-L-lysine)
  - id: CHEBI:50594
    label: Carbon nanotubes
  - id: HP:0007663
    label: Reduced visual acuity
  - id: MAXO:0000016
    label: cellular therapy
  - id: CHEBI:19226
    label: Tm
  - id: MONDO:0017385
    label: mucopolysaccharidosis type I (MPSI) Hurler
  - id: MAXO:0000018
    label: Biomarker assessment
  - id: HP:0001138
    label: Optic neuropathy
  - id: HP:0000488
    label: Retinopathy
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:33310
    label: MCT (NE)
  - id: HP:0001367
    label: joint disease
  - id: HP:0002652
    label: skeletal dysplasia
  - id: HP:0000618
    label: vision impairments
  - id: HP:0000365
    label: hearing impairments
  - id: MONDO:0007147
    label: Obstructive sleep apnea syndrome (OSAS)
  - id: MAXO:0000915
    label: Overnight polysomnography (PSG)
  - id: HP:0002104
    label: Apnea
  - id: HP:0040213
    label: Hypopnea
  - id: MAXO:0010033
    label: Umbilical cord blood transplantation
  - id: MONDO:0009290
    label: Pompe Disease
  - id: HP:0005162
    label: Left ventricular failure
  - id: HP:0011675
    label: Conduction abnormalities
  - id: HP:0001677
    label: Coronary artery disease
  - id: HP:0001433
    label: Hepatosplenomegaly
